Department of Internal Medicine, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
PLoS One. 2023 Feb 6;18(2):e0277213. doi: 10.1371/journal.pone.0277213. eCollection 2023.
We hypothesize that synbiotic supplementation could modulate the intestinal microbiota and subsequently, improve the condition of hypothyroid patients.
Fifty-six adult hypothyroid patients were recruited to this double-blind, placebo-controlled, randomized clinical trial. The intervention was 10 weeks of synbiotic (500 mg of 109 CFU/g probiotics plus fructo-oligosaccharide, n = 28) compared to placebo (lactose, magnesium stearate, talc, and silicon dioxide, n = 28). Randomization and allocation to trial groups were carried out using random number sequences drawn from https://sealedenvelope.com/. Primary outcomes were serum thyroid stimulating hormone (TSH) and free thyroxine (FT4), and secondary outcomes were depression, quality of life, and blood pressure (BP). P-values< 0.05 were considered statistically significant.
Analysis on 51 patients who completed the trial showed that TSH and depression (p> 0.05) did not change significantly, while serum FT4 significantly increased in both groups (p = 0.03 and p = 0.02 in symbiotic and placebo respectively). A significant decrease in systolic BP occurred only in the synbiotic group (p = 0.05). Significant improvements occurred regarding different domains and areas of quality of life in the crude and adjusted analysis, including perceived mental health (p = 0.02), bodily pain (p = 0.02), general health perception (p = 0.002), and wellbeing (p = 0.002), which were significantly higher in the synbiotic group.
Ten-week supplementation with synbiotic had no favorable effect on depression and TSH, but it improved blood pressure and quality of life in patients with hypothyroidism. More trials are needed to support or reject these findings.
IRCT20210926052583N1, Iranian Registry of Clinical Trials (IRCT), registered October 1st, 2021.
我们假设共生元补充剂可以调节肠道微生物群,进而改善甲状腺功能减退患者的病情。
这项双盲、安慰剂对照、随机临床试验招募了 56 名成年甲状腺功能减退患者。干预措施是 10 周的共生元(500 毫克 109CFU/g 益生菌加果寡糖,n=28)与安慰剂(乳糖、硬脂酸镁、滑石粉和二氧化硅,n=28)相比。随机分组和分配到试验组是通过从 https://sealedenvelope.com/ 中提取随机数序列来进行的。主要结局指标是血清促甲状腺激素(TSH)和游离甲状腺素(FT4),次要结局指标是抑郁、生活质量和血压(BP)。p 值<0.05 被认为具有统计学意义。
对完成试验的 51 名患者进行分析显示,TSH 和抑郁(p>0.05)没有明显变化,而两组血清 FT4 均显著增加(共生元组 p=0.03 和 p=0.02,安慰剂组 p=0.03 和 p=0.02)。只有在共生元组中,收缩压才显著下降(p=0.05)。在未经调整和调整后的分析中,生活质量的不同领域和方面都有显著改善,包括感知心理健康(p=0.02)、身体疼痛(p=0.02)、总体健康感知(p=0.002)和幸福感(p=0.002),共生元组的这些指标显著更高。
10 周的共生元补充剂对抑郁和 TSH 没有有利影响,但改善了甲状腺功能减退患者的血压和生活质量。需要更多的试验来支持或否定这些发现。
IRCT20210926052583N1,伊朗临床试验注册中心(IRCT),于 2021 年 10 月 1 日注册。